BAMCO Inc
NTLA icon

BAMCO Inc’s Intellia Therapeutics NTLA Stock Holding History

BAMCO Inc’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-16,200
Closed -$907K – 384
2022
Q3 		$907K Buy
+16,200
New +$1M ﹤0.01% 333
2022
Q1 		– Sell
-10,400
Closed -$1.23M – 410
2021
Q4 		$1.23M Buy
+10,400
New +$1.3M ﹤0.01% 368

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BAMCO Inc's NTLA Position: Q4 2022 in Review

BAMCO Inc sold out of Intellia Therapeutics (NTLA) in Q4 2022, closing a stake of 16,200 shares — an estimated $907K sold.

BAMCO Inc first reported a position in NTLA in Q4 2021 and held it in 2 quarters. The position peaked at $1.23M in Q4 2021. 302 funds tracked by Wall St. Rank hold NTLA as of Q4 2022.

  • BAMCO Inc reported no remaining Intellia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • BAMCO Inc sold 16,200 Intellia Therapeutics shares in Q4 2022, an estimated $907K.
  • BAMCO Inc first reported a position in Intellia Therapeutics in Q4 2021 and held it in 2 quarters.
  • BAMCO Inc's Intellia Therapeutics position peaked at $1.23M in Q4 2021.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2022.

Based on BAMCO Inc's 13F filing for Q4 2022, filed 14 Feb 2023.